Table 2—

Changes of characteristics from baseline to 6 months after treatment with either rosiglitazone in 30 subjects or placebo in 34 subjects

RosiglitazonePlacebo
Body weight3.0 ± 2.4§−0.4 ± 1.9
BMI1.20 ± 1.00§−0.18 ± 0.79
Systolic blood pressure−0.3 ± 15.7*−8.1 ± 16.3
Diastolic blood pressure−0.4 ± 8.0−1.1 ± 7.4
Fasting plasma glucose−10.6 ± 41.017.8 ± 58.5
Fasting plasma insulin−1.07 ± 4.87−1.16 ± 4.72
Insulin resistance−0.19 ± 0.47*0.04 ± 0.60
Insulin secretion−1.20 ± 12.80−3.11 ± 8.31
HbA1c−0.7 ± 1.00.4 ± 1.3
  • Data are means ± SD.

  • *

    * P < 0.1;

  • P < 0.05;

  • P < 0.005;

  • §

    § P < 0.0005 compared with the placebo group by student’s t test.